Last updated: August 12, 2026
GLYSET, the U.S. brand for miglitol, is a mature oral antihyperglycemic with limited commercial value. FDA approved GLYSET in 1996 for adjunctive treatment of adults with type 2 diabetes. The product competes against inexpensive generic miglitol, acarbose, metformin, DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 therapies. Its commercial position has weakened because of modest efficacy, gastrointestinal tolerability issues, frequent dosing and the availability of newer diabetes medicines with stronger cardiovascular, renal and weight-loss profiles.
Public company filings do not disclose standalone GLYSET revenue. The financial trajectory is therefore best characterized qualitatively: initial branded sales after approval, loss of meaningful exclusivity, generic substitution, declining brand relevance and a low-value mature-generic market.
What is GLYSET and how does miglitol work?
GLYSET contains miglitol, an alpha-glucosidase inhibitor. It delays intestinal carbohydrate digestion and reduces postprandial glucose excursions. The product is administered orally with the first bite of each main meal in 25 mg, 50 mg and 100 mg strengths.[1]
Miglitol does not stimulate insulin secretion. Its clinical effect is concentrated on postprandial glucose rather than fasting glucose. The FDA label identifies flatulence, diarrhea and abdominal discomfort as common adverse reactions. These effects result from undigested carbohydrates reaching the colon.[1]
The drug has several commercial limitations:
- It requires administration with each main meal.
- Dose escalation is needed to improve tolerability.
- Gastrointestinal adverse events can reduce adherence.
- It has limited impact on weight and does not carry the outcome-driven cardiovascular and renal positioning associated with newer agents.
- It is less convenient than once-daily oral and injectable alternatives.
When did GLYSET receive FDA approval and lose exclusivity?
FDA approved GLYSET in 1996 under New Drug Application 20-282 for adults with type 2 diabetes.[1] The product was developed and originally marketed by Bayer.
The commercially important exclusivity period ended years ago. GLYSET is no longer a protected branded growth product, and generic miglitol has been available in the U.S. market. The relevant commercial event was the transition from branded pricing to generic competition, not a recent patent cliff.
| Milestone |
Approximate timing |
Commercial effect |
| FDA approval of GLYSET |
1996 |
Launch of branded miglitol |
| Initial U.S. branded period |
Late 1990s to early 2000s |
Premium pricing and physician promotion |
| Generic entry and loss of exclusivity |
2000s |
Price erosion and reduced brand demand |
| Mature generic phase |
2010s onward |
Low-volume, low-margin market |
| Current strategic position |
Present market |
Limited value as a standalone branded asset |
FDA approval does not establish current commercial availability. The product’s practical market status depends on active manufacturer listings, wholesaler supply and pharmacy substitution. Generic miglitol remains the relevant competitive product even where branded GLYSET is no longer actively promoted.
What is the Orange Book status of GLYSET?
GLYSET’s Orange Book relevance is limited because the product is an old small-molecule medicine with generic competition. The FDA Orange Book is the primary source for approved products, therapeutic equivalence and listed patents or exclusivity.[2]
The key conclusions are:
- GLYSET does not have a commercially meaningful period of remaining market exclusivity.
- Generic miglitol is the primary substitution risk.
- The drug is not a biologic and therefore has no biosimilar pathway.
- Any residual patent rights would need to be evaluated against the specific NDA, patent listing and enforceability record rather than assumed from historical compound patents.
- No current branded patent position is known to support premium pricing.
For diligence purposes, the relevant legal question is not whether historical miglitol patents existed. It is whether any unexpired, Orange Book-listed patent would block an approved generic product. The mature generic status of miglitol indicates that such a barrier is not commercially material.
What patents protect GLYSET and miglitol?
The core composition and development patents for miglitol are old. Any original compound or use patents would have expired under the ordinary U.S. patent term framework, subject to the specific filing date, patent term adjustments and any applicable patent-term extension.
No commercially significant active patent estate is associated with GLYSET’s current market position. The product is not known for a durable formulation-patent strategy, extended-release platform or device-based protection.
| Protection category |
GLYSET position |
| Active-ingredient patent |
Historical protection; no material current exclusivity |
| Formulation patent |
No commercially significant current barrier identified |
| Method-of-use patent |
No current method-of-use protection supporting market exclusivity identified |
| Manufacturing patent |
Potential process know-how may exist, but it is not a recognized market barrier |
| Orange Book patent strategy |
Limited practical importance |
| Regulatory exclusivity |
Expired |
| Biosimilar exclusivity |
Not applicable |
What formulations are protected by GLYSET patents?
GLYSET is marketed as an immediate-release oral tablet. Its commercial differentiation does not depend on an extended-release formulation, proprietary delivery system or specialty dosage form.
The tablet strengths are 25 mg, 50 mg and 100 mg.[1] These strengths support titration but do not create a meaningful barrier to generic competition. Generic manufacturers can generally compete through the same active ingredient, dosage form and strength once regulatory requirements are satisfied.
A formulation strategy would have required a differentiated product such as reduced gastrointestinal exposure, less frequent dosing or improved tolerability. GLYSET has not established such a commercially important formulation franchise.
Which companies are challenging GLYSET, and are there Paragraph IV risks?
The principal competitive threat is ordinary generic substitution rather than an active, high-value Paragraph IV campaign. Paragraph IV litigation is most commercially important before generic entry, when a branded product has substantial remaining sales and unexpired listed patents. That profile does not fit GLYSET.
Potential generic entrants would challenge any listed patents by asserting invalidity, unenforceability or non-infringement under the Hatch-Waxman framework. Because GLYSET is a mature product, the economic value of a new Paragraph IV challenge is limited unless supply is constrained or generic pricing is unusually high.
The competitive landscape includes:
- Generic miglitol manufacturers.
- Generic acarbose manufacturers.
- Metformin suppliers.
- DPP-4 inhibitor manufacturers.
- SGLT2 inhibitor manufacturers.
- GLP-1 receptor agonist manufacturers.
- Insulin and combination-therapy suppliers.
Generic miglitol is the closest direct substitute. The broader therapeutic competition is more important commercially because physicians can select other glucose-lowering therapies with better adherence, efficacy or outcome data.
What is the litigation status for GLYSET?
No major current patent litigation affecting GLYSET is a recognized driver of market value. The product’s commercial risk is primarily demand erosion, generic pricing and supply availability.
Historical litigation, if any, would have greater relevance to the original generic-entry period than to current valuation. A litigation search should distinguish:
- Patent cases involving the active ingredient.
- ANDA litigation involving miglitol tablets.
- Product-liability cases.
- Manufacturing or supply disputes.
- Trademark disputes involving the GLYSET name.
There is no established basis to treat GLYSET as a current litigation-sensitive asset. No settlement agreement is known to define a meaningful future launch restriction for generic miglitol.
Does GLYSET face biosimilar risk?
No. GLYSET contains miglitol, a chemically synthesized small molecule. It is regulated through the conventional drug approval and ANDA framework, not the biologic license application and biosimilar framework.
The relevant entry mechanism is generic substitution. Generic manufacturers must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements. Biosimilar interchangeability standards do not apply.
How does GLYSET compare with competing diabetes drugs?
GLYSET has a low-cost and low-systemic-exposure profile but weak commercial differentiation.
| Drug class |
Typical commercial advantage over miglitol |
GLYSET disadvantage |
| Metformin |
Low price, strong guideline position, once- or twice-daily use |
Miglitol has more frequent gastrointestinal dosing |
| DPP-4 inhibitors |
Convenient oral dosing and better tolerability |
Miglitol has weaker adherence profile |
| SGLT2 inhibitors |
Cardiovascular, renal and heart-failure positioning |
Miglitol lacks comparable outcome data |
| GLP-1 receptor agonists |
Strong glucose, weight and outcome benefits |
Miglitol has limited efficacy and no weight-loss franchise |
| Acarbose |
Same broad mechanism and established use |
Direct class competition and similar gastrointestinal concerns |
| Insulin |
High glucose-lowering potency |
Miglitol is easier to administer but less effective in advanced disease |
GLYSET can retain niche use where postprandial glucose control and low acquisition cost are priorities. That niche is small relative to the growth markets for SGLT2 inhibitors and GLP-1 therapies.
What is the financial trajectory of GLYSET?
No reliable standalone public revenue series for GLYSET is available. Bayer and subsequent large pharmaceutical companies generally reported portfolio-level or therapeutic-area sales rather than product-level GLYSET revenue. Public filings therefore do not support a precise revenue forecast, peak-sales estimate or current brand valuation.
The financial trajectory can be divided into four phases:
Branded launch phase
After FDA approval, GLYSET generated revenue as a differentiated oral diabetes therapy. Sales depended on physician adoption, reimbursement and the willingness of patients to tolerate gastrointestinal effects.
Mature branded phase
The product faced competition from metformin, sulfonylureas, insulin and other oral agents. Its value proposition remained narrow because the drug primarily improved postprandial glucose and required meal-time dosing.
Generic transition
Generic entry reduced net price, prescribing control and manufacturer incentives. Pharmacy substitution shifted demand away from the GLYSET brand.
Mature generic phase
Current value is driven by manufacturing cost, supply reliability, regulatory compliance and wholesaler access. Revenue opportunity is likely low in absolute terms, with limited pricing power and little rationale for substantial promotional spending.
What market dynamics affect generic miglitol?
Generic miglitol operates in a price-sensitive market with limited demand growth. The key variables are:
- Prescription volume. Diabetes prevalence supports baseline demand, but miglitol captures only a small share of treatment.
- Generic pricing. Multiple suppliers can reduce prices, while a small supplier base can create temporary price increases.
- Manufacturing economics. Low-volume products may become unattractive if active pharmaceutical ingredient, quality-control and regulatory costs rise.
- Pharmacy substitution. Automatic substitution generally favors generic miglitol over GLYSET.
- Clinical prescribing. Newer drugs continue to displace older postprandial agents.
- Supply continuity. A shortage can temporarily increase sales for remaining suppliers without changing long-term market size.
- Reimbursement. Formularies typically favor low-cost generic products but may not prioritize miglitol when other low-cost diabetes options are available.
What generic launch scenarios exist for GLYSET?
Base case: stable low-volume generic market
Generic miglitol remains available from a limited number of manufacturers. Prices remain low, and prescription volume declines gradually as newer therapies replace alpha-glucosidase inhibitors.
Downside case: further therapeutic displacement
Clinicians increasingly use SGLT2 inhibitors, GLP-1 receptor agonists and fixed-dose combinations. Miglitol prescriptions fall, leaving a smaller market with weaker manufacturing economics.
Supply-constrained case: temporary price expansion
One or more suppliers exit, creating shortages or wholesaler gaps. Remaining manufacturers may experience higher volumes and improved pricing, but the effect would likely be temporary.
Upside case: narrow cost-driven niche
Payers or health systems emphasize low acquisition cost for patients who require postprandial control and cannot use preferred alternatives. This could stabilize generic demand but is unlikely to restore branded economics.
How strong is the GLYSET patent estate?
The patent estate is weak from a current commercial perspective. Historical patent protection supported the original branded launch, but the relevant exclusivity has expired. There is no identified formulation, delivery, method-of-use or manufacturing barrier capable of preventing ordinary generic substitution.
The strongest remaining assets are likely regulatory knowledge, manufacturing capability, supplier relationships and market access. These are operational advantages rather than exclusionary intellectual property.
What licensing deals affect GLYSET?
No current licensing transaction is known to create material value for GLYSET. Historical commercialization arrangements may have involved Bayer, regional affiliates or later portfolio transfers, but the product’s mature-generic status limits the economic significance of legacy licensing.
A potential transaction involving miglitol would be assessed primarily on:
- Current annual prescription volume.
- Net realized price.
- Manufacturing cost.
- API supply security.
- Product quality history.
- FDA compliance.
- Number of approved competitors.
- Wholesale and pharmacy access.
- Potential shortage exposure.
The asset would fit a low-cost generic portfolio more naturally than an innovation-focused pharmaceutical platform.
What is the FDA regulatory status of GLYSET?
FDA approved GLYSET for adjunctive use with diet and exercise in adults with type 2 diabetes.[1] The label includes renal dosing and contraindication considerations, including significant renal impairment and diabetic ketoacidosis.[1]
The regulatory risk is conventional for an old oral solid dosage product. Key issues include:
- Continued compliance with current good manufacturing practices.
- Bioequivalence for generic products.
- Label maintenance.
- Pharmacovigilance.
- Product quality and supply continuity.
- Accurate reporting of active and discontinued marketing status.
No pediatric, orphan, biologic or breakthrough-designation value is associated with GLYSET.
Key Takeaways
- GLYSET is the original U.S. brand for miglitol, an alpha-glucosidase inhibitor approved in 1996.
- Its branded exclusivity has expired, and generic miglitol is the relevant commercial product.
- No current patent estate is known to block generic competition.
- Formulation and method-of-use patents do not provide a meaningful current moat.
- Biosimilar risk is not applicable because miglitol is a small-molecule drug.
- No major current litigation or settlement is known to drive market access.
- Standalone GLYSET revenue is not disclosed in public company filings.
- The financial trajectory is one of branded maturation, generic erosion and low-value mature-market stabilization.
- Competitive pressure from metformin, SGLT2 inhibitors, GLP-1 therapies and DPP-4 inhibitors is stronger than the direct threat from another branded miglitol product.
- Current investment value would depend on manufacturing economics, supply constraints and portfolio fit rather than innovation or patent protection.
FAQs
Is GLYSET still sold in the United States?
The brand’s commercial relevance is limited, while generic miglitol is the primary market product. FDA approval status and active commercial distribution are separate questions.
Is miglitol cheaper than GLP-1 drugs?
Generic miglitol generally has a lower acquisition cost than GLP-1 receptor agonists, but the products have materially different efficacy, dosing, weight and outcomes profiles.
Can a company obtain new patents on miglitol?
A company could seek patents for a genuinely novel formulation, manufacturing process or use, but an old active ingredient cannot normally receive a new composition-of-matter patent merely because it is commercialized by a different sponsor.
Does GLYSET have orphan-drug exclusivity?
No. GLYSET is an established type 2 diabetes drug and is not associated with orphan-drug exclusivity.
What would make generic miglitol financially attractive?
The strongest catalysts would be a supply shortage, competitor withdrawal, improved manufacturing costs or a niche reimbursement policy that preserves demand. None would create the durable growth profile associated with a patented diabetes product.
References
-
U.S. Food and Drug Administration. (2018). Glyset (miglitol) tablets prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: Glyset (miglitol), NDA 020282. FDA.
-
DailyMed. (2024). Miglitol tablet labeling. National Library of Medicine.
-
U.S. Food and Drug Administration. (1984). Hatch-Waxman amendments and abbreviated new drug application requirements. FDA.
